{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:15:52Z","timestamp":1793092552608,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024068","name":"Universit\u00e4t Witten\/Herdecke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jpet.2025.103639","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:49:05Z","timestamp":1750420145000},"page":"103639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Alzheimer disease: Amyloid peptide controversies and challenges of anti-A\u03b2 immunotherapy"],"prefix":"10.1016","volume":"392","author":[{"given":"Najlaa Hamed","family":"Almohmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-Kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-8897","authenticated-orcid":false,"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-8549","authenticated-orcid":false,"given":"Ahmed M.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"El-Saber Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11064-022-03817-4","article-title":"A potential link between visceral obesity and risk of Alzheimer\u2019s disease","volume":"48","author":"Al-Kuraishy","year":"2023","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10787-022-01099-4","article-title":"Benzodiazepines in Alzheimer\u2019s disease: beneficial or detrimental effects","volume":"31","author":"Al-Kuraishy","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jpet.2025.103639_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102084","article-title":"The link between metabolic syndrome and Alzheimer disease: a mutual relationship and long rigorous investigation","volume":"91","author":"Al-Kuraishy","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10787-023-01163-7","article-title":"Long-term use of metformin and Alzheimer\u2019s disease: beneficial or detrimental effects","volume":"31","author":"Al-Kuraishy","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jpet.2025.103639_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102684","article-title":"Beyond amyloid plaque, targeting \u03b1-synuclein in Alzheimer disease: the battle continues","volume":"105","author":"Al-Kuraishy","year":"2025","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jpet.2025.103639_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121532","article-title":"Insights on benzodiazepines\u2019 potential in Alzheimer\u2019s disease","volume":"320","author":"Al-Kuraishy","year":"2023","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13760-023-02403-x","article-title":"The probable role of tissue plasminogen activator\/neuroserpin axis in Alzheimer\u2019s disease: a new perspective","volume":"124","author":"Ali","year":"2024","journal-title":"Acta Neurol Belg"},{"issue":"7","key":"10.1016\/j.jpet.2025.103639_bib8","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s10571-023-01392-y","article-title":"Primary hypothyroidism and Alzheimer\u2019s Disease: a tale of two","volume":"43","author":"AlAnazi","year":"2023","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib10","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jpet.2025.103639_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102119","article-title":"Evaluation and targeting of amyloid precursor protein (APP)\/amyloid beta (A\u03b2) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel","volume":"92","author":"Al-Kuraishy","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"12","key":"10.1016\/j.jpet.2025.103639_bib12","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00018-019-03404-x","article-title":"Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPP\u03b1)","volume":"77","author":"Dar","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10.1016\/j.jpet.2025.103639_bib13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/brainsci12101290","article-title":"Statins use in Alzheimer disease: bane or boon from frantic search and narrative review","volume":"12","author":"Alsubaie","year":"2022","journal-title":"Brain Sci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/bc.bc_42_19","article-title":"Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review","volume":"6","author":"Al-Kuraishy","year":"2020","journal-title":"Brain Circ"},{"key":"10.1016\/j.jpet.2025.103639_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ijbiomac.2020.07.327","article-title":"Role of tau protein in Alzheimer\u2019s disease: the prime pathological player","volume":"163","author":"Muralidar","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jpet.2025.103639_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","article-title":"A current view on Tau protein phosphorylation in Alzheimer\u2019s disease","volume":"69","author":"Wegmann","year":"2021","journal-title":"Curr Opin Neurobiol"},{"issue":"10043","key":"10.1016\/j.jpet.2025.103639_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jpet.2025.103639_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between A\u03b2 and Tau in the Pathogenesis of Alzheimer\u2019s Disease","volume":"17","author":"Zhang","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.jpet.2025.103639_bib19","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/molecules27061816","article-title":"Role of cholinergic signaling in Alzheimer\u2019s disease","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jpet.2025.103639_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"190","author":"Marucci","year":"2021","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.jpet.2025.103639_bib21","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.jpet.2025.103639_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102012","article-title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer\u2019s disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis","volume":"90","author":"Jeremic","year":"2023","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jpet.2025.103639_bib24","doi-asserted-by":"crossref","DOI":"10.2196\/68454","article-title":"Clinical benefits and risks of antiamyloid antibodies in sporadic Alzheimer disease: systematic review and network meta-analysis with a web application","volume":"27","author":"Jeremic","year":"2025","journal-title":"J Med Internet Res"},{"issue":"8","key":"10.1016\/j.jpet.2025.103639_bib25","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213483","article-title":"Incidence of amyloid-related imaging abnormalities in phase III clinical trials of anti-amyloid-\u03b2 immunotherapy: an updated meta-analysis","volume":"104","author":"Jeong","year":"2025","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12264-019-00429-x","article-title":"Early intervention in Alzheimer\u2019s disease: how early is early enough?","volume":"36","author":"Fan","year":"2020","journal-title":"Neurosci Bull"},{"issue":"12","key":"10.1016\/j.jpet.2025.103639_bib27","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170228","article-title":"The role of astrocytes in amyloid production and Alzheimer\u2019s disease","volume":"7","author":"Frost","year":"2017","journal-title":"Open Biol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116802","article-title":"Cerebrospinal fluid \u03b2-amyloid1-42 levels in the differential diagnosis of Alzheimer\u2019s disease\u2014systematic review and meta-analysis","volume":"10","author":"Mo","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3233\/JAD-220673","article-title":"A review of application of A\u03b242\/40 ratio in diagnosis and prognosis of Alzheimer\u2019s disease","volume":"90","author":"Xu","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.jpet.2025.103639_bib30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ana.22313","article-title":"Endogenous amyloid-\u03b2 is necessary for hippocampal synaptic plasticity and memory","volume":"69","author":"Puzzo","year":"2011","journal-title":"Ann Neurol"},{"issue":"27","key":"10.1016\/j.jpet.2025.103639_bib31","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1523\/JNEUROSCI.2501-19.2020","article-title":"Effect of A\u03b2 oligomers on neuronal APP triggers a vicious cycle leading to the propagation of synaptic plasticity alterations to healthy neurons","volume":"40","author":"Rolland","year":"2020","journal-title":"J Neurosci"},{"key":"10.1016\/j.jpet.2025.103639_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101801","article-title":"Presynaptic failure in Alzheimer\u2019s disease","volume":"194","author":"Barthet","year":"2020","journal-title":"Prog Neurobiol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-2010-1230","article-title":"A physiological role for amyloid-\u03b2 protein: enhancement of learning and memory","volume":"19","author":"Morley","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.jpet.2025.103639_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The amyloid cascade hypothesis in Alzheimer\u2019s disease: it\u2019s time to change our mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jpet.2025.103639_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1326-9-48","article-title":"Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease","volume":"9","author":"Tu","year":"2014","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41398-022-02132-4","article-title":"Early impairment of cortical circuit plasticity and connectivity in the 5XFAD Alzheimer\u2019s disease mouse model","volume":"12","author":"Chen","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jpet.2025.103639_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/srep32553","article-title":"Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric A\u03b242: an early index of Alzheimer\u2019s disease","volume":"6","author":"Koppensteiner","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.jpet.2025.103639_bib38","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/nn.4163","article-title":"Decreased amyloid-\u03b2 and increased neuronal hyperactivity by immunotherapy in Alzheimer\u2019s models","volume":"18","author":"Busche","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jpet.2025.103639_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnagi.2017.00071","article-title":"Early-onset network hyperexcitability in presymptomatic Alzheimer\u2019s disease transgenic mice is suppressed by passive immunization with anti-human APP\/A\u03b2 antibody and by mGluR5 blockade","volume":"9","author":"Kazim","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.jpet.2025.103639_bib40","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.1523\/JNEUROSCI.1334-10.2010","article-title":"BACE1 deficiency causes altered neuronal activity and neurodegeneration","volume":"30","author":"Hu","year":"2010","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.jpet.2025.103639_bib41","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.neurobiolaging.2013.05.013","article-title":"Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds","volume":"34","author":"Joseph-Mathurin","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"13","key":"10.1016\/j.jpet.2025.103639_bib42","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1523\/JNEUROSCI.23-13-05531.2003","article-title":"The production of amyloid \u03b2 peptide is a critical requirement for the viability of central neurons","volume":"23","author":"Plant","year":"2003","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1101\/lm.1310209","article-title":"Amyloid beta mediates memory formation","volume":"16","author":"Garcia-Osta","year":"2009","journal-title":"Learn Mem"},{"issue":"35","key":"10.1016\/j.jpet.2025.103639_bib44","doi-asserted-by":"crossref","first-page":"30797","DOI":"10.1074\/jbc.M505249200","article-title":"Phenotypic and biochemical analysis of BACE1- and BACE2-deficient mice","volume":"280","author":"Dominguez","year":"2005","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.jpet.2025.103639_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042665","article-title":"APP knockout mice experience acute mortality as the result of ischemia","volume":"7","author":"Koike","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103639_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.brainres.2014.02.049","article-title":"Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury","volume":"1560","author":"Pajoohesh-Ganji","year":"2014","journal-title":"Brain Res"},{"issue":"11","key":"10.1016\/j.jpet.2025.103639_bib47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14712598.2024.2416947","article-title":"A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer\u2019s disease","volume":"24","author":"Chhabra","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.jpet.2025.103639_bib48","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103639_bib49","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib50","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s disease and the \u03b2-amyloid peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.jpet.2025.103639_bib52","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jpet.2025.103639_bib54","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijbiomac.2021.03.113","article-title":"The role of amyloid oligomers in neurodegenerative pathologies","volume":"181","author":"Wells","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jpet.2025.103639_bib55","article-title":"Role of A\u03b2 in Alzheimer\u2019s-related synaptic dysfunction","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-025-00479-4","article-title":"Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer\u2019s disease: a comprehensive review of the characteristics and therapeutic strategies","volume":"14","author":"Nam","year":"2025","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100013","article-title":"Microglial activation states and their implications for Alzheimer\u2019s disease","volume":"12","author":"Valiukas","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.jpet.2025.103639_bib58","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/1073858420954811","article-title":"Cerebral amyloid angiopathy and blood-brain barrier dysfunction","volume":"27","author":"Gireud-Goss","year":"2020","journal-title":"Neuroscientist"},{"issue":"8","key":"10.1016\/j.jpet.2025.103639_bib59","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/pro.3906","article-title":"Progress toward Alzheimer\u2019s disease treatment: leveraging the Achilles\u2019 heel of A\u03b2 oligomers?","volume":"29","author":"Fantini","year":"2020","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13041-024-01118-1","article-title":"The duality of amyloid-\u03b2: its role in normal and Alzheimer\u2019s disease states","volume":"17","author":"Azargoonjahromi","year":"2024","journal-title":"Mol Brain"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nrl.2015.03.012","article-title":"Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein","volume":"33","author":"Folch","year":"2018","journal-title":"Neurologia (Engl Ed)"},{"issue":"10","key":"10.1016\/j.jpet.2025.103639_bib62","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1517\/14712598.2014.935332","article-title":"Amyloid-directed monoclonal antibodies for the treatment of Alzheimer\u2019s disease: the point of no return?","volume":"14","author":"Panza","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","article-title":"Amyloid-based immunotherapy for Alzheimer\u2019s disease in the time of prevention trials: the way forward","volume":"10","author":"Panza","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib64","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib66","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12967-024-05248-x","article-title":"Passive immunotherapy for Alzheimer\u2019s disease: challenges & future directions","volume":"22","author":"Yi","year":"2024","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.jpet.2025.103639_bib67","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","article-title":"Bapineuzumab and solanezumab for Alzheimer\u2019s disease: is the \u2018amyloid cascade hypothesis\u2019 still alive?","volume":"13","author":"Tayeb","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1386207326666230419095813","article-title":"Safety analysis of bapineuzumab in the treatment of mild to moderate Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"27","author":"Gao","year":"2024","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.jpet.2025.103639_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1147757","article-title":"Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-\u00e0-vis placebo in mild or moderate Alzheimer\u2019s disease","volume":"14","author":"Hao","year":"2023","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103639_bib70","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer\u2019s disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jpet.2025.103639_bib71","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1002\/alz.13031","article-title":"Targeting amyloid \u03b2 in Alzheimer\u2019s disease: meta-analysis of low-dose solanezumab in Alzheimer\u2019s disease with mild dementia studies","volume":"19","author":"Holdridge","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib72","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.aggp.2024.100016","article-title":"Efficacy and safety of gantenerumab in the treatment of Alzheimer\u2019s disease: A meta-analysis of randomized controlled trials","volume":"1","author":"Sobral","year":"2024","journal-title":"Arch Gerontol Geriatr Plus"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab\u2014binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib75","article-title":"Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer\u2019s disease","volume":"10","author":"Teipel","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"16 suppl","key":"10.1016\/j.jpet.2025.103639_bib76","article-title":"Long-term safety and tolerability of escalating doses of crenezumab in patients with mild-to-moderate Alzheimer\u2019s disease (P6.083)","volume":"88","author":"Asnaghi","year":"2017","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.jpet.2025.103639_bib77","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"15 suppl","key":"10.1016\/j.jpet.2025.103639_bib78","article-title":"Baseline characteristics from a phase III trial of crenezumab in early (prodromal-to-mild) Alzheimer\u2019s disease (CREAD) (P4.1-002)","volume":"92","author":"Sink","year":"2019","journal-title":"Neurology"},{"issue":"supp1","key":"10.1016\/j.jpet.2025.103639_bib79","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies as promising disease-modifying therapies in Alzheimer\u2019s disease: a focus on aducanumab, lecanemab, crenezumab, gantenerumab and solanezumab","volume":"66","author":"Melo","year":"2023","journal-title":"Eur Psychiatry"},{"issue":"11","key":"10.1016\/j.jpet.2025.103639_bib80","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ana.25513","article-title":"Target engagement in an Alzheimer trial: Crenezumab lowers amyloid \u03b2 oligomers in cerebrospinal fluid","volume":"86","author":"Yang","year":"2019","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trci.2017.04.003","article-title":"Multiple-dose ponezumab for mild-to-moderate Alzheimer\u2019s disease: Safety and efficacy","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimer Dement (N Y)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib83","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/acn3.761","article-title":"Immunotherapy with ponezumab for probable cerebral amyloid angiopathy","volume":"6","author":"Leurent","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpet.2025.103639_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","article-title":"Lecanemab (BAN2401): an anti\u2013beta-amyloid monoclonal antibody for the treatment of Alzheimer disease","volume":"32","author":"Vitek","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/healthcare11010032","article-title":"Donanemab for Alzheimer\u2019s disease: a systematic review of clinical trials","volume":"11","author":"Rashad","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.jpet.2025.103639_bib87","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1742-2094-10-70","article-title":"Intravenous immunoglobulin and Alzheimer\u2019s disease: what now?","volume":"10","author":"Loeffler","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103639_bib89","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5582\/ddt.2023.01215","article-title":"Development of amyloid beta-directed antibodies against Alzheimer\u2019s disease: twists and turns","volume":"17","author":"Lu","year":"2023","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.jpet.2025.103639_bib90","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1742-2094-9-105","article-title":"Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer\u2019s disease","volume":"9","author":"Puli","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt237","article-title":"Active immunotherapy options for Alzheimer\u2019s disease","volume":"6","author":"Winblad","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib92","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jamaneurol.2019.4182","article-title":"Active immunotherapy to prevent Alzheimer disease\u2014a DNA amyloid \u03b2 1-42 trimer vaccine","volume":"77","author":"Rosenberg","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103639_bib93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/antib12020041","article-title":"Recent trends in active and passive immunotherapies of Alzheimer\u2019s disease","volume":"12","author":"Alshamrani","year":"2023","journal-title":"Antibodies"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib94","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","article-title":"Immunotherapy for Alzheimer\u2019s disease","volume":"88","author":"Wisniewski","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1750-3639.2005.tb00102.x","article-title":"Immunological and anti-chaperone therapeutic approaches for Alzheimer disease","volume":"15","author":"Wisniewski","year":"2005","journal-title":"Brain Pathol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib96","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic A\u03b242 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"issue":"3-4","key":"10.1016\/j.jpet.2025.103639_bib97","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","article-title":"Progress in the active immunotherapeutic approach to Alzheimer\u2019s disease: clinical investigations into AN1792-associated meningoencephalitis","volume":"5","author":"Pride","year":"2008","journal-title":"Neurodegener. Dis"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib98","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archneur.64.4.583","article-title":"Absence of \u03b2-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia","volume":"64","author":"Bombois","year":"2007","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103639_bib99","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","article-title":"A\u03b2 species removal after A\u03b242 immunization","volume":"65","author":"Nicoll","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"10.1016\/j.jpet.2025.103639_bib100","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"S3","key":"10.1016\/j.jpet.2025.103639_bib101","article-title":"An integrated systems-level analysis of the molecular changes resulting from systemic inflammation and amyloid-beta immunisation in Alzheimer\u2019s disease","volume":"18","author":"MacBean","year":"2022","journal-title":"Alzheimer Dement (N Y)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimer Dement (N Y)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib103","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/alz.13532","article-title":"Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE \u03b54 homozygotes","volume":"20","author":"Riviere","year":"2024","journal-title":"Alzheimer Dement"},{"issue":"6","key":"10.1016\/j.jpet.2025.103639_bib104","article-title":"Attempts to develop vaccines against Alzheimer\u2019s disease: a systematic review of ongoing and completed vaccination trials in humans","volume":"15","author":"Thakur","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib105","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.jpet.2025.103639_bib106","first-page":"192","article-title":"A randomized, double-blind, phase 2 study of the effects of the vaccine vanutide cridificar with QS-21 adjuvant on immunogenicity, safety and amyloid imaging in patients with mild to moderate Alzheimer\u2019s disease","volume":"3","author":"Ketter","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"issue":"S10","key":"10.1016\/j.jpet.2025.103639_bib107","article-title":"Optimized ACI-24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and pyroglutamate Abeta, key pathological species of Alzheimer\u2019s disease (AD)","volume":"18","author":"Fiorini","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib108","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/cells12010079","article-title":"Beneficial effect of ACI-24 vaccination on A\u03b2 plaque pathology and microglial phenotypes in an amyloidosis mouse model","volume":"12","author":"Rudan Njavro","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jpet.2025.103639_bib109","series-title":"Direct Nose-to-Brain Drug Delivery","first-page":"351","article-title":"Intranasal gene therapy for the treatment of neurological disorders","author":"Dhas","year":"2021"},{"issue":"3","key":"10.1016\/j.jpet.2025.103639_bib110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","article-title":"Development of AFFITOPE vaccines for Alzheimer\u2019s disease (AD) \u2014 from concept to clinical testing","volume":"13","author":"Schneeberger","year":"2009","journal-title":"J Nutr Health Aging"},{"issue":"1","key":"10.1016\/j.jpet.2025.103639_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115237","article-title":"Tailoring the antibody response to aggregated A\u03b2 using novel Alzheimer-vaccines","volume":"10","author":"Mandler","year":"2015","journal-title":"PLoS One"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:14:23Z","timestamp":1756376063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":111,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0022356525398526"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103639","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer disease: Amyloid peptide controversies and challenges of anti-A\u03b2 immunotherapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103639"}}